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 A majority of the asthma population had one of the comorbidities measured and few had 
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ABSTRACT 
Purpose: 
To examine occurrence of chronic diseases and antimicrobial treatment in an asthma 
population 8-29 years old, compared to the general population.  
 
Methods: 
In this cross-sectional study, the asthma population was identified from the general population 
(retrieved from a census covering the entire Norwegian population) by using filled 
prescriptions on asthma drugs as a proxy measure of current asthma. The outcome was excess 
occurrence of specific diseases (comorbidity) among asthmatics, compared to the age-specific 
general population. Diseases were defined by filled prescriptions with specific diagnostic 
codes with asthma, compared with the age-specific general population. Diseases were 
defined by filled prescriptions with specific diagnostic codes (International Classification of 
Primary Care 2nd edition [ICPC-2] or International Classification of Diseases 10th revision 
[ICD-10]) during a 1-year period in the Norwegian Prescription Database. Nine chronic 
diseases were examined: ADHD, epilepsy, migraine, mental illness, cardiovascular disease, 
diabetes, autoimmune disorders, gastro-oesophageal reflux disease (GORD), allergy. 
Additionally, antibacterials recommended for respiratory tract infections and antivirals were 
examined (defined by ATC codes). Standardized Morbidity Ratios (SMR) for each disease 
was calculated. 
 
Results: 
59% of the population had at least one of nine chronic diseases examined, compared to 18% 
in the general population. Few individuals had more than one additional chronic disease (6% 
of males, 8% of females). SMRs were increased for all diseases except diabetes, implying 
higher than expected occurrence of the specific diseases in asthmatics. This pattern was 
observed in both age groups (8-19 and 20-29 years) and genders. Allergy and GORD had 
highest SMR (range 3.2-4.8) while the other diseases were in the range 1.2-2.5. 
 
Conclusions: 
An excess occurrence of comorbidities was found in the population with asthma. A majority 
of asthmatics had one additional chronic disease, and few had more than one. 
 
  
  
INTRODUCTION 
There is increasing recognition that co-occurrence of multiple chronic diseases is common 
also in children and has a significant impact on the overall health of patients.
1-3
 The extent and 
impact of comorbidities in asthmatics has received little attention compared to other chronic 
diseases like cardiovascular diseases and diabetes, possibly because multimorbidity increases 
with age
1
 while asthma is most prevalent in young populations.  
 
From the societal point of view, health service use is higher in asthmatics with comorbidities 
and places an extra burden on the healthcare system.
4,5
 At the patient level, comorbidities 
influence several aspects of asthma, such as detection, diagnosis, severity and the control of 
asthma symptoms.
6-8
 Identification and treatment of comorbidities is part of the core 
management of asthma, especially for more severe cases.
9
 Associations between asthma and 
allergy, gastro-oesophageal reflux disease (GORD) and infections are well-established
9-12
 
while several other diseases have also been associated with asthma in population-based 
studies.
7,13-15
 However, few studies include children and adolescents.  
 
There is currently no systematic recording of diagnostic information in the Norwegian home-
dwelling population. Thus, opportunities to study the occurrence of diseases in the population 
have been limited. However, a change in the reimbursement system for drugs may enable us 
to assess occurrence of diseases in the entire population. From March 2009, it became 
mandatory to provide the diagnostic code (International Classification of Primary Care 2nd 
edition [ICPC-2] or International Classification of Diseases 10th revision [ICD-10]) of the 
treated medical condition on all reimbursed prescriptions. The Norwegian Prescription 
Database (NorPD)
16
 is one of the first nationwide prescription databases to record this 
information. These codes may serve as surrogate measures of the diseases present among 
individuals in ambulatory care. The diseases studied in the present paper have been associated 
with asthma in previous population-based studies
7,13-15
, are expected to be of some magnitude 
in this young population. Furthermore, drug treatment is central to the management of the 
disease, and drugs are reimbursable. 
 
The aim of the present study was to examine the occurrence of specific types of chronic 
diseases and antimicrobial treatment in an actively treated asthma population of children, 
adolescents and young adults, compared to the occurrence in the Norwegian general 
population of the same age.  
MATERIALS AND METHODS 
Data sources and study design 
We conducted a cross-sectional study utilizing data from three datasets covering the entire 
Norwegian population. The datasets were linked by using the unique, encrypted 11-digit 
person identity number (PIN), assigned to all individuals residing in Norway.
16
 
 
The latest Population and Housing Census (PHC) included all persons resident in Norway on 
3
rd
 November 2001 according to the Central Population Register (CPR).
17
 The PHC provided 
  
  
a closed cohort of all Norwegians residents and variables used were the PIN, gender and birth 
year.  
 
The Central Population Register (CPR) contains continuously updated data on every person 
residing in Norway.
18
 The CPR provided information on date of death and emigration 
between the PHC in 2001 and the end of the study period. 
 
The Norwegian Prescription Database (NorPD) stores electronic data on all filled 
prescriptions from Norwegian pharmacies since January 2004. Pharmacies are obliged to send 
the data, irrespective of reimbursement status of the dispensed drugs and the prescribers’ 
specialty and occupation.
16
 Thus, NorPD has complete coverage of drugs dispensed to the 
home-dwelling population. Variables from NorPD used in the present study were the PIN, 
date of dispensing drug, reimbursement code (diagnostic code from March 2009) and the 
Anatomical Therapeutic Chemical (ATC)
19
 classification code of drugs.  
Measure of comorbidities 
Diagnostic codes from reimbursed drug prescriptions registered in NorPD were used to define 
the outcome (comorbidities). 
 
Reimbursement scheme with diagnostic codes: Reimbursement of drug costs is a part of the 
national, tax-supported public health service which all Norwegians have unrestricted access 
to.
20
 The drug reimbursement scheme is based on a list of conditions for which specified 
drugs can be reimbursed. Reimbursement should only be granted if the patient has a chronic 
condition where long term treatment is needed (at least 3 months of regular or intermittent 
treatment during a year). From March 2009, physicians were obliged to provide the diagnostic 
code of the condition being treated on prescriptions deemed eligible for reimbursement. 
Codes from either the International Classification of Diseases version 10 (ICD-10) or the 
International Classification of Primary Care version 2 (ICPC-2) can be used. The Norwegian 
Medicines Agency (NoMA) has defined about 20 additional codes for conditions that have no 
appropriate ICD-10 and/or ICPC-2 code, some of which has been included in our study (see 
comments in Table 1).  
 
Occurrence of a comorbid disease: The presence of a comorbid chronic disease in an 
individual was defined as filling at least one reimbursed prescription with a diagnostic code 
during a 1-year period. These diagnostic codes were used as a surrogate measure of disease. 
The following nine chronic diseases were examined: Attention Deficit Hyperactivity Disorder 
(ADHD, denoted “hyperkinetic disorder” in ICD-10 and ICPC-2), epilepsy, migraine, mental 
illness, cardiovascular disease, diabetes (type 1 and 2), autoimmune disorders, gastro-
oesophageal reflux disease (GORD) and allergy (Table 1).  
To study occurrence of antimicrobial treatment (normally not reimbursed), ATC codes 
on drugs dispensed were used instead of diagnostic codes (Table 1). Antibacterials 
recommended in Norwegian guidelines21 for use in upper and lower respiratory tract 
infections were included, as well as antivirals used for influenza virus infections. 
Comorbidity may be defined as the occurrence of one or more additional diseases in 
individuals who have an index disease.
22
 For brevity, the term “comorbidity” will be used in 
the present paper for the occurrence of any of the diseases also in the general population who 
do not necessarily have the index disease (asthma). 
 
  
  
Index date and study period: From 3 March 2009, physicians were obliged to write diagnostic 
codes on all reimbursed prescriptions, and this date was therefore set as the index date. NorPD 
data on the outcome (comorbidity) for a 1-year period after the index date was retrieved for 
the Norwegian general population and for the study population with asthma.  
Standard population: Norwegian general population 
The standard population included all persons who participated in the PHC in 2001 and were 
under 30 years in 2009 (653,386 males, 620,453 females). Individuals who according to CPR 
data died or emigrated before the end of the study period (2 March 2010) were excluded 
(16,282 males, 18,024 females). Thus, 637,104 male and 602,429 female residents in Norway 
aged 8-29 years in 2009 comprised the standard population. Because the PHC was conducted 
in 2001, the lowest age class that could be studied was 8 years old. 
Study population: Individuals with current asthma in the general population 
The study population was patients with asthma currently receiving drug treatment that could 
be identified in the standard population (20,207 males, 16,853 females). A proxy measure 
based on dispensed asthma drugs was used to identify this population, a measure described in 
previous NorPD studies.
23,24
 Included were those who had filled prescription for an asthma 
drug at least once in the year before and at least once in the year after the index date. Only 
prescriptions with reimbursement codes for asthma were included. Asthma drugs were 
defined as inhaled β2-agonists (ATC code R03AC), inhaled glucocorticoids (R03BA), 
combination inhalers with β2-agonists and glucocorticoids (R03AK), and leukotriene receptor 
antagonists (R03DC).  
Statistical methods 
The number of comorbidities occurring in the asthma population and in the general population 
was examined as the proportion of the populations having respectively 0, 1, 2, 3, and 4 or 
more comorbidities (Table 2). 
 
Associations of asthma with specific comorbidities were examined by calculating 
Standardized Morbidity Ratios (SMR) (Table 3). The occurrence of each disease (prevalence 
proportion) was calculated for 1-year age-specific groups in the general population and 
separately for males and females. From these prevalence proportions, Expected counts (E) in 
the asthma population were calculated, while Observed counts (O) were retrieved in the same 
manner as for the general population. The O/E ratio (SMR) was calculated with 95% CIs from 
the Poisson distribution. Results were stratified by gender and age (8-19 years and 20-29 
years). Note that the magnitude of the SMRs is not directly comparable between the different 
genders and age groups, because they are based on different standard populations.  
 
The study was approved by the Norwegian Data Inspectorate, and the Regional Committee 
for Medical Research Ethics evaluated it. 
  
  
RESULTS 
Occurrence of nine chronic comorbidities was studied. 59% of male and female asthmatics 
had at least one of the comorbidities, compared to 18% of males and females in the general 
population (Table 2). Relatively few in the asthma population had more than one of these 
comorbidities (6% of males, 8% of females). When antimicrobial treatment was included, 
69% of male and 71% of female asthmatics had at least one comorbidity, compared to 30% 
and 34% in the general population. 
 
The occurrence of specific comorbidities in the asthma population is presented in Table 3. 
The prevalence proportion (O/n) of the asthma population having allergy was above 50% for 
all groups, and antibacterial treatment was also relatively prevalent (14-32%). The prevalence 
was higher in the oldest age group for all comorbidities except allergy in males, ADHD and 
antivirals. The largest percentage point difference in prevalence between the low and high age 
group were observed for migraine in females and for mental illness, as well as for the highly 
prevalent comorbidities (allergy, antimicrobials). 
 
The SMR estimates generally showed an increased occurrence for all diseases, except 
diabetes (Table 3). This pattern was consistent in all gender and age groups and implies a 
higher than expected occurrence of the specific diseases in the asthma population compared to 
the gender- and age-specific general population. GORD and allergy had high SMRs (range 
3.2-4.8). The other diseases were in the range 1.3-2.1, except for diabetes and ADHD which 
showed inconsistent patterns.  
 
Diabetes was the only disease that did not have a consistent increased SMR for the asthma 
population, and was even below 1.0 for the youngest females. In an additional analysis, we 
only included the diagnostic codes that are more specific for diabetes type 1 (ICPC “T89 
Insulin-dependent diabetes mellitus”, and ICD “E10 Diabetes mellitus type I”). This gave 
SMR of 1.3 [1.0-1.6] for the youngest males and 1.1 [0.8-1.5] for the oldest males. For 
females, the numbers were respectively 0.8 [0.5-1.1] and 0.9 [0.6-1.3].  
DISCUSSION 
In this study of children, adolescents and young adults, we found that chronic diseases were 
present more often in asthmatics than in the general population. Likewise, use of specific 
antimicrobial treatments occurred more frequently among individuals with asthma. The 
present study is the first to examine asthma and comorbid diseases in the entire Norwegian 
population by using the diagnostic codes from NorPD. Our results obtained from diagnostic 
codes on prescriptions are essentially in line with studies that obtained diagnostic information 
from administrative data or self-reports. 
7,13-15
 However, most studies are in adults and few 
have reported age-stratified results. 
 
Adams et al.
14
 found associations of asthma and diabetes but not arthritis in adults 18-34 years 
old, but an association was present in older age groups. Cazzola et al.
13
 reported hypertension, 
allergic rhinitis, diabetes, dyslipidemia, depression and GORD to be associated with asthma. 
Associations were generally weaker in 15-34 year olds compared to older adults except for 
allergic rhinitis, depression and diabetes. Prosser et al.
15
 found asthma to be associated with a 
wide range of diseases in adults, including infections in the lower and upper respiratory tract, 
depression, hypertension, diabetes and certain autoimmune disorders. Zhang et al.
7
 found 
  
  
associations with allergy, arthritis/rheumatism, hypertension, diabetes and mental illness in an 
adult population. Most chronic conditions were more prevalent in adults but allergies and 
mental illness were more frequent in 18-34 year olds.  
 
In studies of specific diseases, anxiety and depression has been associated with asthma
25-27
 
and a bidirectional relationship has been suggested.
25
 The association may be dependent on 
how asthma is defined.
28,29
 Asthma has been found to be associated with migraine in 
adults.
30,31
 In studies comparing epileptics to non-epileptics, an association with asthma has 
been reported.
32,33
 ADHD and asthma are most prevalent in children and adolescents, and this 
is reflected in our data by ADHD being one of the more prevalent comorbidities of asthma. 
Associations with ADHD have been reported in the literature, including a NorPD study that 
used ATC codes as proxy measures for diagnosis of both diseases.
34,35
 Associations between 
diabetes and asthma has been found in several studies in adults. 
7,13-15
 Our data had relatively 
few diabetes cases in the asthma population and did not show a consistent association. Of note 
is that a high proportion of participants in our young study population are expected to be type 
1 diabetics, while studies among adults will be predominated by type 2 diabetics. For GORD, 
the absolute numbers (prevalence) is lower in asthmatics in our study than reported in the 
literature among children
11
 and adults
12
, possibly because it has not been diagnosed and 
subsequently treated with prescription drugs (over-the-counter drugs are also available). 
However, the strong relative association (SMR) is reported in other studies as well.
11,12
 Links 
between asthma and allergies and respiratory infections are well known and receive much 
attention in asthma guidelines.
9,10
 An association between asthma and antibacterials is 
difficult to disentangle from associations of asthma and infections themselves, and the present 
study was not designed for this purpose. 
 
Our measure of comorbidity will capture chronic diseases diagnosed by a physician, where 
the physician and the patient have chosen to treat with drugs in the ambulatory setting. The 
study is cross-sectional and the temporal sequence events can not be determined. The 
associations observed may have several explanations and we will discuss three possibilities.  
 
First, there may be a genuinely increased co-occurrence of other diseases in individuals with 
asthma. This may be due to a pathway where one problem is central to development of the 
other. For example, the comorbidity may be a risk factor for development of asthma, or for 
triggering asthma symptoms or increasing severity. The causal link may be reversed, in that 
asthma contributes to development of other diseases. Alternatively, asthma and comorbidities 
may be indirectly linked via common genetic and environmental factors for development of 
disease.  
 
Second, there may be a higher detection rate of comorbidities in individuals with asthma, i.e. 
detection bias occurs.
36
 This may be an issue in any epidemiologic study where health care 
service use is measured. Asthmatics do more often than their healthy peers visit physicians for 
monitoring of the disease and prescription renewals. Any additional health problems more 
easily come to the attention of physicians and a prescription for a drug may ensue. This may 
also go the opposite direction in that asthma is more easily detected in individuals who have 
other reasons for visiting a physician. This kind of bias is probably most pertinent in milder, 
intermittent cases of asthma, and for comorbidities with a high proportion of subclinical cases 
that are not usually detected. An increased detection rate of diabetes and epilepsy seems less 
likely due to the severity of these diseases. Furthermore, our definition of the asthma 
population will have excluded some milder cases of asthma and individuals who tried asthma 
drugs only once as part of diagnosing respiratory complaints. 
  
  
 
Third, some individuals may have a lower threshold for seeking healthcare services including 
drug treatment, and/or some physicians have a lower threshold for setting a diagnosis and 
prescribing drugs. Use of healthcare services may be a learned behavior where individuals 
with asthma who often are in contact with their physician will likely be more aware of their 
illnesses and may have learned to use, and possibly overuse, healthcare services. In support of 
the latter explanation are studies reporting a higher occurrence of a broad range of different 
conditions in asthmatics.
5,7,13-15
 It would be interesting to find a “reference disease” that is not 
linked to asthma and study if there is an excess occurrence of this “reference disease”.  
 
The asthma drugs used to identify our asthma population are the mainstay of asthma 
pharmacotherapy
9
 and are quite specifically used for asthma at this age. Largely all patients 
on anti-asthma treatment in Norway receive at least one of the included drugs
23
 and a high 
validity of this measure was found in 7-year olds.
24
 In the present study, we used a stricter 
criterion for defining the asthma population in that individuals with asthma had to fill at least 
two prescriptions and at least 1 year apart. Thus, the inception of asthma complaints took 
place before the 1-year study period and lasted for at least one year (persistently or episodes 
of asthma at least one year apart).  
 
A limitation of the study is the cross-sectional design which unable us to determine a causal 
relationship between comorbidities and the occurrence of asthma. The recording of diagnostic 
codes has only recently been implemented but when more years of data are accumulated, 
long-term studies can be done to confirm our findings and to disentangle the sequence of 
events. The time period of one year may be too short to capture some comorbidities, e.g. 
individuals with infrequent episodes of migraine may have long gaps between prescription 
refills. The length of study period is especially pertinent when studying a time-varying disease 
such as asthma where disease activity and the use of asthma drugs
23
 is variable over shorter 
and longer time periods. A possible detection bias was discussed above. A further limitation is 
that for allergy and GORD, over-the-counter drugs without reimbursement are available. 
Some individuals may also have used non-reimbursed prescription drugs. This is probably 
most relevant for migraine and mental illnesses, if the physician deems the disease as not 
chronic or not properly diagnosed yet. Patients have economic incentives for receiving their 
drugs on reimbursement but acquiring a prescription may be more convenient for patients due 
to higher physician visit frequency.  
 
One of the strengths of our study is that we use individual level data from three complete, 
nationwide datasets. NorPD captures all individuals receiving prescription drugs in the 
ambulatory care setting, including drugs prescribed by specialists in secondary and tertiary 
care. The universal healthcare system should ensure access to necessary healthcare services 
for all residents. Thus, we could examine the occurrence of a broad range of diseases in the 
Norwegian general population of the entire age range. The method for identifying chronic 
diseases is consistent between diseases and does not rest on subjective judgment by patients 
about their disease as in self-report studies, while recall bias is eliminated. However, the 
choice by patients and physicians to use drugs for a medical condition may be influenced by 
subjective judgments, as discussed above. 
 
Comorbidities may influence and complicate several aspects of asthma, such as detection, 
diagnosis, severity and the control of asthma symptoms.
6-8
 Furthermore, the response to 
asthma therapy may be altered (e.g., obesity alter response to corticosteroids
37
) or adherence 
  
  
to asthma therapy decreases (e.g., depression
28,38
). The drugs used for the treatment of 
comorbid diseases can have detrimental effects on asthma (e.g., NSAIDs
9
). 
 
In summary, by using a nationwide prescription database with diagnostic codes we have 
shown an excess occurrence of several chronic diseases in the young population with asthma, 
compared with the age-specific general population of Norway. Fifty-nine percent of the 
asthma population had at least one additional chronic disease, while relatively few had more 
than one additional disease. 
  
  
Table 1: Comorbidities and corresponding diagnostic codes (ICPC-2 and ICD-10 codes) 
examined in the Norwegian Prescription Database (NorPD). 
Comorbidity ICPC-2 ICD-10 Comment
Attention Deficit Hyperactivity 
Disorder (ADHD)
a
P81 F90 a) Denoted as hyperkinetic disorder in 
ICPC and ICD coding systems.
Epilepsy N88 G40
Migraine N89 G43
Mental distress (depression, 
anxiety)
-74
b;
 P74; 
P76
-74
b;
 F41; 
F32
b) Reimbursement code for anxiety 
disorders, defined by NoMA (replaces 
ICPC and ICD codes).
Cardiovascular disease 
(hypercholesterolemia, 
hypertension)
-26
c; 
-27
c; 
K86-87
-26
c;
 -27
c; 
I10-13; I15
c) Reimbursement codes for primary and 
secondary prevention of atherosclerotic 
disease, defined by NoMA (replaces ICPC 
and ICD codes).
Diabetes
d
 (Type 1, type 2) T89-90 E10-11; 
E13-14
d) ICPC codes do not distinguish between 
diabetes type 1 and 2.
Autoimmune disorders
(Arthritis-related diseases, 
systemic connective tissue 
disorders, ankylosing spondylitis, 
noninfective enteritis and colitis, 
psoriasis)
L88; L99; 
D94; S91
M05-08; M13; 
M30-35; M45; 
K50-51; L40
Gastro-oesophageal reflux 
disease (GORD)
e
D84 K21 e) OTC drugs also on market but are not 
reimbursed.
Allergy
f 
(Allergic rhinitis, allergic 
conjunctivitis, atopic dermatitis, 
urticaria)
R97; F71; 
S87; S98
J30; 
H10.1
g
; 
L20; L50
f) OTC drugs also on market but are not 
reimbursed.
g) NoMA specifies that only the 4th level 
code H10.1 is eligible for reimbursement.
Antibacterials
h 
(upper and lower 
respiratory tract)
h) Drugs (ATC codes) recommended by 
guidelines
†
 for treatment of upper and 
lower respiratory tract infections.
Antivirals
i 
(influenza virus 
infection)
i) H1N1 influenza during study period. 
Pharmacists could write prescriptions and 
dipsense drugs according to set 
regulations, without consulting physicians.
†
 Norwegian Directorate of Health. [Norwegian national guidelines for treatment with antibiotics in general practice]. 2008. Available from: 
   http://www.helsebiblioteket.no/microsite/Antibiotikaretningslinjer (in Norwegian).
C
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a
s
e
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ATC codes: 
J05AH01; J05AH02 
ATC, Anatomical Therapeutic Chemical classification system for drugs; ICD-10, International Statistical Classification of Diseases, 10th 
revision; ICPC-2, International Classification of Primary Care, 2nd edition; NoMA, Norwegian Medicines Agency; OTC, over-the-counter-
drugs (drugs sold without precription);
ATC codes: 
J01AA02; J01CA04; 
J01CE02; J01FA
a
n
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m
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b
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l 
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e
a
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n
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Table 2: Number of comorbid diseases occurring in the asthma population and the general 
population (8-29 years old) during a 1-year period. 
 
% of asthma 
population
a
% of general 
population
% of asthma 
population
a
% of general 
population
(n=20,207) (n=637,104) (n=16,853) (n=602,429)
Chronic diseases
b
0 40.8 82.4 41.4 81.9
1 53.3 16.2 50.4 16.2
2 5.3 1.3 6.9 1.6
3 0.6 0.1 1.0 0.2
4+ 0.1 0.0 0.2 0.0
0 30.7 70.2 29.1 66.4
1 48.2 24.3 44.6 26.3
2 17.3 4.8 20.0 6.1
3 3.3 0.6 5.2 1.0
4+ 0.5 0.1 1.1 0.2
a) Not adjusted to the age-distribution of the general poulation.
c) 11 different comorbidities measured, see Table 1.
b) 9 different comorbidities measured, see Table 1.
Male subjects Female subjects
Chronic diseases and 
antimicrobial treatment
c
Number of 
comorbidities
 
  
  
Table 3: Standardized Morbidity Ratio (SMR) for occurrence of comorbid diseases in the 
asthma population (8-29 years old) during a 1-year period (Reference: Occurrence of diseases 
in the general population by gender and 1-year age specific groups). 
Occurrence 
(O/n)
Observed 
count (O)
Expected 
count (E)
SMR 
(O/E)
Occurrence 
(O/n)
Observed 
count (O)
Expected 
count (E)
SMR 
(O/E)
ADHD 4.0 % 585 469 1.2 [1.1 , 1.4] 2.2 % 223 129 1.7 [1.5 , 2.0]
Epilepsy 1.0 % 149 84 1.8 [1.5 , 2.1] 1.1 % 111 56 2.0 [1.6 , 2.4]
Migraine 0.9 % 133 76 1.7 [1.5 , 2.1] 2.0 % 203 118 1.7 [1.5 , 2.0]
Mental illness 0.4 % 65 39 1.7 [1.3 , 2.1] 0.9 % 90 67 1.3 [1.1 , 1.7]
Cardiovascular 0.1 % 20 13 1.5 [1.0 , 2.3] 0.2 % 21 12 1.8 [1.1 , 2.7]
Diabetes 0.6 % 83 62 1.3 [1.1 , 1.7] 0.4 % 37 43 0.9 [0.6 , 1.2]
Autoimmune 0.7 % 103 66 1.6 [1.3 , 1.9] 1.0 % 104 67 1.5 [1.3 , 1.9]
GORD 1.6 % 236 52 4.6 [4.0 , 5.2] 1.3 % 134 34 4.0 [3.3 , 4.7]
Allergy 56.1 % 8258 1,977 4.2 [4.1 , 4.3] 51.8 % 5274 1,098 4.8 [4.7 , 4.9]
Antibacterials
d 13.8 % 2024 1,212 1.7 [1.6 , 1.7] 19.6 % 1994 1,212 1.6 [1.6 , 1.7]
Antivirals
d,e 13.8 % 2033 986 2.1 [2.0 , 2.2] 13.1 % 1330 684 1.9 [1.8 , 2.1]
ADHD 1.6 % 89 39 2.3 [1.8 , 2.8] 1.6 % 108 42 2.5 [2.1 , 3.1]
Epilepsy 1.3 % 69 39 1.8 [1.4 , 2.2] 1.4 % 93 49 1.9 [1.6 , 2.3]
Migraine 1.1 % 60 37 1.6 [1.3 , 2.1] 5.6 % 370 198 1.9 [1.7 , 2.1]
Mental illness 4.5 % 249 134 1.9 [1.6 , 2.1] 7.7 % 510 266 1.9 [1.8 , 2.1]
Cardiovascular 1.3 % 69 39 1.8 [1.4 , 2.2] 1.2 % 77 40 1.9 [1.5 , 2.4]
Diabetes 0.8 % 45 41 1.1 [0.8 , 1.5] 1.0 % 64 46 1.4 [1.1 , 1.8]
Autoimmune 1.9 % 104 80 1.3 [1.1 , 1.6] 2.8 % 188 121 1.5 [1.3 , 1.8]
GORD 3.3 % 179 56 3.2 [2.8 , 3.7] 2.7 % 183 52 3.5 [3.0 , 4.0]
Allergy 51.5 % 2831 591 4.8 [4.6 , 5.0] 55.9 % 3729 903 4.1 [4.0 , 4.3]
Antibacterials
d 22.9 % 1259 777 1.6 [1.5 , 1.7] 31.7 % 2113 1,370 1.5 [1.5 , 1.6]
Antivirals
d,e 9.7 % 534 251 2.1 [2.0 , 2.3] 11.1 % 739 389 1.9 [1.8 , 2.0]
Female subjects
b
Comorbidity
c
c) Indviduals that have more than one comorbidity is counted on each comorbidity (sum of observed counts (O) on all comorbidities does not equate to the 
study population size).
d) From ATC codes on drugs.
e) H1N1 influenza epidemic occured during the observed 1-year period.
[95% CI]
ADHD, Attention Deficit Hyperactivity Disorder (hyperkinetic disorder); GORD, Gastro-oesophageal reflux disease; SMR, standardized morbidity ratio.
a) Males n=20,207 (8-19 years n=14,709; 20-29 years n=5.498).
b) Females n=16,853 (8-19 years n=10,187; 20-29 years n=6,666).
[95% CI]
Male subjects
a
8-19 years 
20-29 years
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